| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4097817 | The Spine Journal | 2014 | 6 Pages |
Background contextRecombinant human bone morphogenetic protein-2 (rhBMP-2) is commonly used to augment posterior and interbody spinal fusion techniques and has many reported side effects. Neuroforaminal heterotopic ossification (HO) is a known cause of postoperative leg pain, but the pathohistologic composition of this material is not well understood.PurposeThe purpose of this article was to report the histologic composition of a case of HO and lumbar radiculopathy after transforaminal lumbar interbody fusion with rhBMP-2.Study design/settingThis is a case report.Patient sampleThis is a single patient case report.Outcome measuresThe outcomes considered were physician-recorded clinical, physiological, and functional measures.MethodsA retrospective review of a single patient was performed. Clinical, radiographic, and pathologic specimens were reviewed and are reported.ResultsA 69-year-old woman presented with low back pain and right leg radicular pain associated with L4–L5 stenosis and a recurrent facet cyst. After attempted nonsurgical care, she underwent an L4–L5 revision decompression with interbody and posterolateral fusions including off-label rhBMP-2. Postoperatively, her symptoms resolved for approximately 7 months but then returned in association with right L4–L5 foraminal HO. The ectopic tissue was notably larger than suggested by preoperative computed tomographic scan. It was decompressed, which then improved her symptoms. Histologic examination of the specimen revealed three discrete tissue types: a nonspecific fibrovascular stroma; immature osteoid and woven bone; and chondrocyte metaplasia with chondrocyte clustering.ConclusionsNeuroforaminal HO formation is a reported side effect associated with the off-label use of rhBMP-2 for posterior lumbar interbody fusion. The mechanism of formation and the composition of this material are not well understood but may involve a chondrocyte differentiation pathway.
